JPWO2020264065A5 - - Google Patents

Claims (14)

a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:13 (H-CDR1); the amino acid sequence of SEQ ID NO:15 (H-CDR2); and the amino acid sequence of SEQ ID NO:17 (H-CDR3), and the amino acid sequence of SEQ ID NO:19 (L-CDR1); the amino acid sequence of SEQ ID NO:22 (L-CDR2); and the amino acid sequence of SEQ ID NO:24 (L-CDR3) or a light chain variable region comprising the amino acid sequence of SEQ ID NO:14 (H-CDR1); a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 15 (H-CDR2); and the amino acid sequence of SEQ ID NO: 17 (H-CDR3); and the amino acid sequence of SEQ ID NO: 19 (L-CDR1); L-CDR2); and a light chain variable region comprising the amino acid sequence of SEQ ID NO:24 (L-CDR3) or the amino acid sequence of SEQ ID NO:13 (H-CDR1); the amino acid sequence of SEQ ID NO:15 (H-CDR2); a heavy chain variable region comprising the amino acid sequence of No. 16 (H-CDR3); and the amino acid sequence of SEQ ID No. 20 (L-CDR1); the amino acid sequence of SEQ ID No. 23 (L-CDR2); L-CDR3) or a heavy chain comprising the amino acid sequence of SEQ ID NO: 13 (H-CDR1); the amino acid sequence of SEQ ID NO: 15 (H-CDR2); and the amino acid sequence of SEQ ID NO: 16 (H-CDR3). and the amino acid sequence of SEQ ID NO:21 (L-CDR1); the amino acid sequence of SEQ ID NO:23 (L-CDR2); and the amino acid sequence of SEQ ID NO:25 (L-CDR3) or a light chain variable region or SEQ ID NO: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 13 (H-CDR1); the amino acid sequence of SEQ ID NO: 15 (H-CDR2); and the amino acid sequence of SEQ ID NO: 16 (H-CDR3); -CDR1); the amino acid sequence of SEQ ID NO:22 (L-CDR2); and the amino acid sequence of SEQ ID NO:24 (L-CDR3). SEQ ID NO:3 and SEQ ID NO:8, respectively; SEQ ID NO:4 and SEQ ID NO:9, respectively; SEQ ID NO:5 and SEQ ID NO:10, respectively; SEQ ID NO:6 and SEQ ID NO:11, respectively; or SEQ ID NO:7 and SEQ ID NO:12, respectively. 2. The anti-ANGPT2 antibody of claim 1, comprising a variable heavy chain and a variable light chain. 33 and 34 respectively; 35 and 36 respectively; 37 and 38 respectively; or 39 and 40 respectively; 2. The anti-ANGPT2 antibody of claim 1, comprising a light chain. A pharmaceutical composition comprising the anti-ANGPT2 antibody or antigen-binding fragment of any one of claims 1-3, and optionally a pharmaceutically acceptable carrier . A pharmaceutical composition according to claim 4 for treating a disease or disorder that can be ameliorated by treatment with the anti-ANGPT2 antibody or antigen-binding fragment according to any one of claims 1-3 . Use of the anti-ANGPT2 antibody or antigen-binding fragment of any of claims 1-3 in the manufacture of a medicament for treating a disease or disorder that can be alleviated by treatment with an anti-ANGPT2 antibody. The disease or disorder is cardiac hypertrophy, myocardial infarction, ischemia, ischemic reperfusion injury, stroke hypertension, pulmonary arterial hypertension, idiopathic pulmonary arterial hypertension, trauma-induced brain damage, asthma , chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, preeclampsia and pregnancy-induced hypertension, sepsis, severe sepsis, septic shock, nonalcoholic steatohepatitis (NASH), cirrhosis, minimal changes, focal segmental glomerulosclerosis (FSGS), nephrotic syndrome, diabetic nephropathy (DKD), chronic kidney disease (CKD), diabetic renal failure, end-stage renal disease, ischemia blood or ischemic reperfusion injury, cancer, hepatocellular carcinoma, idiopathic pulmonary fibrosis (IPF), emphysema, acute lung injury (ALI), acute respiratory disease syndrome (ARDS), severe acute respiratory syndrome (SARS), Middle Eastern respiratory syndrome (MERS), vascular hyperpermeability (and related disorders), acute kidney injury, renal cell carcinoma, heart failure, lupus nephritis, Raynaud's, pancreatitis, Peripheral artery disease, congenital heart disease, dengue virus, malaria, hantavirus, edema, regeneration, lupus, interstitial lung disease, scleroderma, retinopathy, diabetic nephropathy, portal hypertension, varices growth ) and liver transplantation . 8. The pharmaceutical composition of claim 7 , or claim, wherein the disease or disorder is selected from the group consisting of chronic kidney disease, non-alcoholic steatohepatitis (NASH), diabetic nephropathy, sepsis and vascular hyperpermeability. Item 8. Use of the anti-ANGPT2 antibody or antigen-binding fragment of Item 7 . 8. The pharmaceutical composition of claim 7 , or the anti-ANGPT2 antibody of claim 7 , wherein the disease or disorder is selected from the group consisting of ALI, ARDS, SARS, MERS and vascular hyperpermeability (and related disorders). Or use of an antigen-binding fragment. 8. The pharmaceutical composition of claim 5 or 7 , administered with a second therapeutic agent. 8. The pharmaceutical composition according to claim 5 or 7 , administered by parenteral , intravenous or subcutaneous route of administration . 5. A pharmaceutical composition according to claim 4 for blocking the function of human ANGPT2 in a human patient. Use of the anti-ANGPT2 antibody or antigen-binding fragment according to any one of claims 1 to 3 in the manufacture of a medicament for blocking the function of human ANGPT2. the heavy chain variable region amino acid sequence comprises any of SEQ ID NOS:3-7, SEQ ID NOS:13-17, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37 or SEQ ID NO:39; the light chain variable region amino acid sequence a heavy chain variable region amino acid sequence or light chain variable region amino acid sequence comprising any of SEQ ID NOS:8-12, SEQ ID NOS:19-26, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38 or SEQ ID NO:40 An isolated polynucleotide encoding sequence.